A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorEli Lilly and Company
About this trial
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Eligibility criteria
Qualifiers
Have type 2 diabetes
Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
Have a BMI ≥ 27 kg/m2
Have a stable body weight (<5% body weight change) for 90 days prior to screening
Disqualifiers
Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes
amylin analogs
Trial design
Treatments tested in this trial
- Eloralintide
- Placebo
Treatment groups
1,035 Participants
are divided into 5 treatment groupsLocations
159Argentina
Asociación de Beneficencia Hospital Sirio LibanésC1419AHN, Buenos Aires Argentina
Centro de Investigaciones Metabólicas (CINME)C1056ABI, Buenos Aires Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaC1425AGC, Buenos Aires Argentina
Investigaciones Medicas Imoba SrlC1056ABH, Buenos Aires Argentina
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov